Patents by Inventor James F. Young
James F. Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160000902Abstract: The present disclosure is directed to compositions and methods for raising immune responses against influenza and respiratory syncytial virus by administering combination immunogenic composition against both viruses at the same time. The combination compositions contain an RSV component and one, two, three, four, or more influenza components. The combination compositions provide a greater immune response than that obtained by separately administering the RSV and influenza components.Type: ApplicationFiled: February 11, 2014Publication date: January 7, 2016Inventors: Gale E. SMITH, Gregg GLENN, Lou FRIES, James F. YOUNG
-
Patent number: 9010378Abstract: The present application relates to fluid liners. One example includes first and second recycled geosynthetic sheets having overlapping portions. A heat welded splice is formed along the overlapping portions creates a fluid seal between the first and second recycled geosynthetic sheets so that the first and second geosynthetic sheets collectively function as a fluid liner.Type: GrantFiled: April 15, 2010Date of Patent: April 21, 2015Inventor: James F. Young
-
Publication number: 20140227309Abstract: The present disclosure is directed to compositions and methods for raising immune responses against influenza and respiratory synctial virus by administering combination immunogenic composition against both viruses at the same time. The combination compositions contain an RSV component and one, two, three, four, or more influenza components. The combination compositions provide a greater immune response than that obtained by separately administering the RSV and influenza components.Type: ApplicationFiled: February 11, 2014Publication date: August 14, 2014Applicant: NOVAVAX, INC.Inventors: Gale E. SMITH, Greg GLENN, Lou FRIES, James F. YOUNG
-
Patent number: 8688141Abstract: In certain embodiments, a method for proximity determination includes receiving one or more network identifiers, each associated with a corresponding network, from a first mobile device. The method further includes receiving one or more network identifiers, each associated with a corresponding network, from a second mobile device. The method further includes processing the network identifiers received from the first and second mobile devices to determine whether the first mobile device and the second mobile device are in proximity to one another.Type: GrantFiled: March 30, 2012Date of Patent: April 1, 2014Assignee: Jambo Networks, Inc.Inventors: Charles S. Ribaudo, James F. Young, Jr.
-
Patent number: 8404236Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.Type: GrantFiled: February 13, 2012Date of Patent: March 26, 2013Assignee: MedImmune, LLCInventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Publication number: 20120329475Abstract: In certain embodiments, a method for proximity determination includes receiving one or more network identifiers, each associated with a corresponding network, from a first mobile device. The method further includes receiving one or more network identifiers, each associated with a corresponding network, from a second mobile device. The method further includes processing the network identifiers received from the first and second mobile devices to determine whether the first mobile device and the second mobile device are in proximity to one another.Type: ApplicationFiled: March 30, 2012Publication date: December 27, 2012Applicant: Jambo Networks, Inc.Inventors: Charles S. Ribaudo, James F. Young, JR.
-
Publication number: 20120141463Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.Type: ApplicationFiled: February 13, 2012Publication date: June 7, 2012Applicant: MedImmune, LLCInventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Publication number: 20120135006Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M?1, and even 1011 M?1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: ApplicationFiled: October 24, 2011Publication date: May 31, 2012Applicant: MedImmune, LLCInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Patent number: 8153133Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: GrantFiled: February 17, 2010Date of Patent: April 10, 2012Assignee: MedImmune, LLCInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Patent number: 8150416Abstract: In certain embodiments, a method for proximity determination includes receiving one or more network identifiers, each associated with a corresponding network, from a first mobile device. The method further includes receiving one or more network identifiers, each associated with a corresponding network, from a second mobile device. The method further includes processing the network identifiers received from the first and second mobile devices to determine whether the first mobile device and the second mobile device are in proximity to one another.Type: GrantFiled: August 8, 2006Date of Patent: April 3, 2012Assignee: Jambo Networks, Inc.Inventors: Charles S. Ribaudo, James F. Young, Jr.
-
Publication number: 20120070447Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: October 18, 2010Publication date: March 22, 2012Applicant: MEDIMMUNE, LLCInventors: JAMES F. YOUNG, SCOTT KOENIG, LESLIE S. JOHNSON, WILLIAM D. HUSE, JEFFREY D. WATKINS, HERREN WU
-
Patent number: 8137670Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored IgE and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of IgE-mediated diseases. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of IgE-mediated diseases.Type: GrantFiled: September 28, 2006Date of Patent: March 20, 2012Assignee: MedImmune, LLCInventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Publication number: 20110158985Abstract: The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life.Type: ApplicationFiled: December 15, 2010Publication date: June 30, 2011Applicant: MEDIMMUNE, LLCInventors: GENEVIEVE LOSONSKY, EDWARD M. CONNOR, JAMES F. YOUNG, HERREN WU, WILLIAM DALL'ACQUA
-
Patent number: 7847082Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: June 1, 2009Date of Patent: December 7, 2010Assignee: MedImmune, LLCInventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Publication number: 20100278813Abstract: The present invention relates to methods for broad spectrum prevention and treatment of viral respiratory infection. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with respiratory syncytial virus (RSV), parainfluenza virus (PIV), and/or human metapneumovirus (hMPV) infection, the methods comprising administering to a subject an effective amount of one or more anti-RSV-antigen antibodies or antigen-binding fragments thereof, one or more anti-hMPV-antigen antibodies or antigen-binding fragments thereof, and/or one or more anti-PIV-antigen antibodies or antigen-binding fragments thereof. In certain embodiments, a certain serum titer of the anti-RSV-antigen antibodies, anti-PIV-antigen antibodies, and/or anti-hMPV-antigen antibodies or antigen-binding fragments thereof is achieved in said subject.Type: ApplicationFiled: December 11, 2007Publication date: November 4, 2010Applicants: MedImmune, Inc., Vironovative B.V.Inventors: James F. Young, Peter Kiener, Albertus Dominicus Erasmus Osterhaus, Ronaldus Adrianus Maria Fouchier
-
Publication number: 20100266614Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M?1, and even 1011 M?1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: ApplicationFiled: May 11, 2010Publication date: October 21, 2010Applicant: MedImmune, LLCInventors: James F. YOUNG, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20100263748Abstract: The present application relates to fluid liners. One example includes first and second recycled geosynthetic sheets having overlapping portions. A heat welded splice is formed along the overlapping portions creates a fluid seal between the first and second recycled geosynthetic sheets so that the first and second geosynthetic sheets collectively function as a fluid liner.Type: ApplicationFiled: April 15, 2010Publication date: October 21, 2010Inventor: James F. Young
-
Publication number: 20100239574Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: ApplicationFiled: February 17, 2010Publication date: September 23, 2010Applicants: MEDIMMUNE, LLC, APPLIED MOLECULAR EVOLUTION, INC.Inventors: JAMES F. YOUNG, LESLIE S. JOHNSON, WILLIAM D. HUSE, HERREN WU, JEFFRY D. WATKINS
-
Patent number: 7740851Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M?1, and even 1011 M?1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: GrantFiled: September 8, 2003Date of Patent: June 22, 2010Assignee: MedImmune, LLCInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20100098708Abstract: The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life.Type: ApplicationFiled: September 14, 2009Publication date: April 22, 2010Applicant: MedImmune, LLCInventors: Genevieve Losonsky, Edward M. Connor, James F. Young, Herren Wu, William Dall'Acqua